These assessments from entities like the Morning Star certainly DO NOT help this company! They say we are overvalued even at .95 cents!! Good grief,,,,what is it that we cant see here?
Analyst Research and Ratings
RVX has underperformed its Biotechnology & Drugs peers over the last three months and over the past year too.
Morningstar's Take
Morningstar's Take
Morningstar Rating |
3 stars out of 5 stars Q |
Quantitative Valuation |
Overvalued |
Fair ValueQ |
0.82 CAD |
Last price as of Feb 22, 2021 |
0.95 CAD |